Print this page
Saturday, 16 July 2016 14:07

Anticoagulation news items. Weeks commencing 11th July 2016

Precision Medicine for Ischemic Stroke

JAMA Neurology

In this article, the authors discuss the future of precision medicine in the field of ischaemic stroke, first looking at the current status of genetic approaches, and then exploring the status of phenotype-based delineations.

 

Volunteers wanted to help determine the future of pharmacovigilance

Medicines and Healthcare products Regulatory Agency

Web-RADR: Recognising Adverse Drug Reactions is running a survey for healthcare providers, patients, and consumers of medicines to help develop the next generation of online side-effect reporting software.

 

New product: ALPROLIX (eftrenonacog alfa) powder and solvent for solution for injection

electronic Medicines Compendium

Eftrenonacog alfa is licensed for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

 

Direct oral anticoagulants: unique properties and practical approaches to management

Heart

This is a review of the indications and dosing considerations, clinical efficacy and safety, laboratory monitoring and reversibility considerations and peri-procedural management of the direct oral anticoagulants (DOACs), highlighting strategies to ensure safe and effective DOAC.

 

European Pharmacovigilance Risk Assessment Committee to begin review of factor VIII medicines for haemophilia A

European Medicines Agency

This review has been initiated following a recent study which suggested that inhibitors develop more frequently in patients on factor VIII (F-VIII) medicines made by DNA recombinant technology than in those receiving (F-VIII) derived from blood.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services